|
Lymphoma
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Variable nuclear expression of BCL10, NFκB1 (p50) and NFκB2 (p52) suggests that other additional genetic abnormalities affecting the NFκB pathway exist within this group of lymphomas.
|
22382892 |
2012 |
|
Lymphoma
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Furthermore, ectopic expression of Bcl-X(L) (but not Bcl-2) in two B-lymphoma cell lines decreased their sensitivity to parthenolide-induced apoptosis.
|
22155272 |
2012 |
|
Lymphoma
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Constitutive NF-kappaB activation in extranodal natural killer (NK)-cell lymphoma, nasal type (ENKL) is known to be associated with aberrant nuclear translocation of BCL10.
|
20235165 |
2010 |
|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
BCL10, required for nuclear factor kappaB (NF-kappaB) activation during antigen-driven lymphocyte responses, is aberrantly expressed in mucosa-associated lymphoid tissue-type marginal zone (MZ) lymphomas because of chromosomal translocations.
|
19696203 |
2009 |
|
Lymphoma
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Bcl10 is a caspase-recruitment domain-containing protein, associated with constitutive activation of NF-kappaB in MALT (mucosa-associated lymphoid tissue) lymphomas.
|
17540779 |
2007 |
|
Lymphoma
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Here we have investigated the mechanisms that control basal and induced expression of Bcl-X(L) in B-lymphoma cells.
|
16983335 |
2007 |
|
Lymphoma
|
0.200 |
AlteredExpression
|
group |
LHGDN |
CIAP2 inhibits anigen receptor signaling by targeting Bcl10 for degredation.
|
16775419 |
2006 |
|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas.
|
16395405 |
2006 |
|
Lymphoma
|
0.200 |
GeneticVariation
|
group |
BEFREE |
To further ascertain whether the detection of t(1;14)(p22;q32) and t(11;18)(q21;q21) can be reliably used for the differential diagnosis between lymphoplasmacytic lymphoma and mucosa-associated lymphoid tissue lymphoma, we screened for these translocations by BCL10 immunohistochemistry in 58 lymphoplasmacytic lymphomas and RT-PCR for t(11;18)(q21;q21) in 40 lymphoplasmacytic lymphomas, respectively.
|
15143341 |
2004 |
|
Lymphoma
|
0.200 |
GeneticVariation
|
group |
BEFREE |
The t(11;18), which produces the putative anti-apoptotic fusion protein API2-MALT1, has been identified in a large proportion of extracutaneous MALT-type lymphomas and a smaller fraction of tumours harbour mutations that inactivate the pro-apoptotic functions of Fas and Bcl10.
|
12950026 |
2003 |
|
Lymphoma
|
0.200 |
GeneticVariation
|
group |
LHGDN |
The occurrence of genomic BCL10 mutations in 35 gastric MALT-type lymphomas with or without t(11;18)(q21;q21) (10 and 25 cases, respectively) was investigated.
|
11830492 |
2002 |
|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
Mutation analysis of BCL10 was then performed on 57 cases of malignant lymphoma, including 17 MALT lymphomas, by single-strand conformational polymorphism (SSCP) analysis of tumour DNA.
|
11748643 |
2002 |
|
Lymphoma
|
0.200 |
GeneticVariation
|
group |
LHGDN |
Lack of Bcl10 mutations in malignant cartilaginous tumors.
|
11836626 |
2002 |
|
Lymphoma
|
0.200 |
AlteredExpression
|
group |
BEFREE |
These results demonstrate that BCL10 mutations are rare in gastric MALT-type lymphoma and are not related to the aberrant nuclear expression of BCL10.
|
11830492 |
2002 |
|
Lymphoma
|
0.200 |
AlteredExpression
|
group |
BEFREE |
BCL10 expression in lymphoma cases was examined by immunohistochemistry.
|
11493468 |
2001 |
|
Lymphoma
|
0.200 |
GeneticVariation
|
group |
BEFREE |
The BCL10 gene, recently isolated due to its involvement in the t(1;14)(p22;q32) of mucosa-associated lymphoid tissue B cell non-Hodgkin lymphoma (MALToma), was shown to have frequent somatic mutations and short deletions within the coding region in MALToma and a variety of other lymphomas and solid tumors.
|
11425462 |
2001 |
|
Lymphoma
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Initially, mutations in the BCL10 gene were reported to occur at a high frequency in various types of lymphomas and solid tumors.
|
11372735 |
2001 |
|
Lymphoma
|
0.200 |
GeneticVariation
|
group |
BEFREE |
These findings were reinforced by direct identification of tumour cells, as recognized by strong BCL10 nuclear staining, in non-lymphomatous lymphocytic infiltrates in the case with t(1;14)(p22;q32).
|
11113866 |
2000 |
|
Lymphoma
|
0.200 |
GeneticVariation
|
group |
BEFREE |
BCL10 gene mutation in lymphoma.
|
10845924 |
2000 |
|
Lymphoma
|
0.200 |
GeneticVariation
|
group |
BEFREE |
BCL10, a gene involved in apoptosis signalling, has recently been identified through the cloning of chromosomal breakpoints in extranodal (MALT-type) marginal zone lymphomas carrying the t(1;14)(p22;q32) translocation.
|
10803524 |
2000 |
|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
Taken together, these data imply that Bcl10 may occasionally be involved in the pathogenesis of lymphoma and GCTs.
|
10582682 |
1999 |
|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
BCL-XL is a potential contributor to the pathogenesis of malignant lymphomas because the BCL-XL isoform is predominantly expressed by the neoplastic cells in the majority of lymphoma cases.
|
9613974 |
1998 |
|
Lymphoma
|
0.200 |
Biomarker
|
group |
HPO |
|
|
|